Havrix Junior Monodose (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior Monodose is indicated for active immunization against hepatitis A virus infection in children according to national immunization schedules.

• Primary prophylaxis of hepatitis A in children aged 12 months and older.
• Completion of a two‑dose series to achieve long‑term protection.
• Use in travelers to regions where hepatitis A is endemic.
• Administration in outbreak settings to quickly raise community immunity.
• Inclusion in combination vaccination programs when approved by health authorities.

Following intramuscular administration, Havrix Junior Monodose may be associated with transient local and systemic reactions, most of which are mild and resolve without intervention.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever occurring within 24‑48 hours.
• Headache or mild fatigue.
• Nausea or mild gastrointestinal discomfort.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome (rare).
• Persistent high fever or severe systemic illness.
• Severe local reaction with extensive necrosis (very rare).

Healthcare providers should evaluate individual risk factors and medical history before administering Havrix Junior Monodose to ensure safe use.

• Defer vaccination in persons with a known severe allergy to any vaccine component, including algeldrate.
• Postpone administration in individuals with acute moderate or severe illness until recovery.
• Use caution in children with immunodeficiency or receiving immunosuppressive therapy.
• Monitor for signs of an allergic reaction for at least 15 minutes after injection.
• Discuss the vaccination schedule with caregivers, especially regarding the timing of the second dose.
• Consider hepatitis A serology testing in those with prior exposure or vaccination.

Havrix Junior Monodose does not have extensive documented drug‑drug interactions, but certain concomitant therapies may influence immune response or safety.

Avoid

• Simultaneous administration with live viral vaccines (e.g., measles, mumps, rubella) unless recommended by guidelines.
• Use in individuals receiving high‑dose immunoglobulin therapy within 2 weeks of vaccination.

Use with caution

• Concurrent use of immunosuppressive agents may reduce antibody response.
• Antipyretics (acetaminophen, ibuprofen) can be given to manage post‑vaccination fever, but should not be prophylactically administered before injection.
• Blood products or plasma containing hepatitis A antibodies may interfere with vaccine efficacy if given within 4 weeks before or after vaccination.